Responses
Inflammatory bowel disease
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
Compose a Response to This Article
Other responses
No responses have been published for this article.